Neutralization, effector function and immune imprinting of Omicron variants
Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots
in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on …
in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on …
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA. 2 and BA. 5 subvariant predominance: A systematic literature …
M Drysdale, M Berktas, DC Gibbons, C Rolland… - Infection, 2024 - Springer
Purpose To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
The impact of vaccination and outpatient treatment on the economic burden of COVID-19 in the United States omicron era: a systematic literature review
V Pierre, F Draica, M Di Fusco, J Yang… - Journal of Medical …, 2023 - Taylor & Francis
Aims To identify and synthesize evidence regarding how coronavirus disease 2019 (COVID-
19) interventions, including vaccines and outpatient treatments, have impacted healthcare …
19) interventions, including vaccines and outpatient treatments, have impacted healthcare …
Molnupiravir, nirmatrelvir/ritonavir, or sotrovimab for high-risk COVID-19 patients infected by the omicron variant: hospitalization, mortality, and time until negative …
L Cegolon, R Pol, O Simonetti, F Larese Filon… - Pharmaceuticals, 2023 - mdpi.com
Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a …
V Patel, MJ Yarwood, B Levick… - Current Medical …, 2024 - Taylor & Francis
Objective To describe characteristics and acute clinical outcomes for patients with COVID-19
treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated patients at highest …
treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated patients at highest …
What is the efficacy of sotrovimab in reducing disease progression and death in people with COVID-19 during the omicron era? Answers from a real-life study
A De Vito, A Colpani, M Poliseno, L Diella, FRP Ieva… - Viruses, 2023 - mdpi.com
(1) Introduction: Since May 2021, sotrovimab has been available in Italy for early treatment
of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro …
of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro …
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy …
T Siripongboonsitti, N Nontawong… - Microbiology …, 2023 - Am Soc Microbiol
The effectiveness of neutralizing monoclonal antibodies against emerging variants with
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
Intramuscular vs intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized noninferiority clinical trial
AE Shapiro, E Sarkis, J Acloque, A Free… - Open forum …, 2023 - academic.oup.com
Background Convenient administration of coronavirus disease 2019 (COVID-19) treatment
in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action …
in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …